2157GCCC:Phase 1 of Calaspargase Pegol-mknl w/ Cytarabine and Idarubicin in Newly Dx AML
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Characterizing the regimen limiting toxicity (RLT) of chemotherapeutic drug Calaspargase
Pegol-mknl as remission induction and consolidation chemotherapy in patients with newly
diagnosed Acute Myeloid Leukemia (AML) and Identifying the Maximum Tolerated Dose (MTD) and
Recommended Phase 2 Dose (RP2D) of Calaspargase Pegol-mknl.